drugset / Trial / NCT02115672
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to test the safety and efficacy of BL-8040 (a CXCR4 antagonist) in improving the response to imatinib in CML patients not achieving an optimal response with imatinib alone.
Timeline
- Start
- 2014-11
- Primary completion
- 2016-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Motixafortide | Peptide | 0.5 mg/kg | Subcutaneous |
| Subject | Motixafortide | Peptide | 1.25 mg/kg | Subcutaneous |